{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T14:44:17Z","timestamp":1793198657810,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T00:00:00Z","timestamp":1660003200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T00:00:00Z","timestamp":1660003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009752","name":"Futurum - Akademin f\u00f6r H\u00e4lsa och V\u00e5rd, Region J\u00f6nk\u00f6pings l\u00e4ns","doi-asserted-by":"publisher","award":["575361"],"award-info":[{"award-number":["575361"]}],"id":[{"id":"10.13039\/501100009752","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010805","name":"Forskningsr\u00e5det i Syd\u00f6stra Sverige","doi-asserted-by":"publisher","award":["932359"],"award-info":[{"award-number":["932359"]}],"id":[{"id":"10.13039\/100010805","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["190224"],"award-info":[{"award-number":["190224"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003945","name":"Link\u00f6ping University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003945","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>We explored the impact of persistent sensory and motor taxane-induced peripheral neuropathy (TIPN) symptoms on health-related quality of life (HRQL) among early-stage breast cancer survivors (ESBCS).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A population-based cohort of 884 residual-free ESBCS received a postal questionnaire, including the EORTC chemotherapy-induced PN (CIPN20) and the EORTC QLQ-C30 instruments. Mean scores of QLQ-C30 scales among ESBCS with and without TIPN were calculated and adjusted for confounding factors (age, lifestyle factors, co-morbidities; linear regression analyses). Interpretation of QLQ-C30 results were based on guidelines.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Response rate was 79%, and 646 survivors were included in the analysis. In median, 3.6 (1.5\u20137.3) years had elapsed post-taxane treatment. All TIPN symptoms had a significant impact on global QoL, which worsened with increased severity of TIPN. Between 29.5% and 93.3% of ESBCS with moderate-severe TIPN reported a clinical important impairment of functioning and personal finances, 64.3\u201385.7% reporting \u201cdifficulty walking because of foot drop,\u201d and 53.1\u201381.3% reporting \u201cproblems standing\/walking because of difficulty feeling ground under feet\u201d had impaired functioning\/finances. The difference in mean scores between affected and non-affected survivors was highest for \u201cnumbness in toes\/feet\u201d and \u201cdifficulty walking because of foot drop.\u201d Moderate-severe \u201cdifficulty climbing stairs or\u00a0getting out of chair because of weakness of legs\u201d and \u201cproblems standing\/walking because of difficulty feeling ground under feet\u201d were associated with the largest clinically important differences on all scales.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Persistent sensory and motor TIPN is associated with clinically relevant impairment of global QoL, functioning, and personal finances among ESBCS, which increased with level of TIPN severity.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10549-022-06670-9","type":"journal-article","created":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T03:51:55Z","timestamp":1660017115000},"page":"379-391","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Impact of persistent peripheral neuropathy on health-related quality of life among early-stage breast cancer survivors: a population-based cross-sectional study"],"prefix":"10.1007","volume":"195","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7291-7227","authenticated-orcid":false,"given":"Kristina","family":"Engvall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Gr\u00e9en","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats","family":"Fredrikson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Lagerlund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freddi","family":"Lewin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7274-1770","authenticated-orcid":false,"given":"Elisabeth","family":"\u00c5vall-Lundqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,9]]},"reference":[{"key":"6670_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"6670_CR2","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1007\/s11136-018-1866-8","volume":"27","author":"ME Schmidt","year":"2018","unstructured":"Schmidt ME, Wiskemann J, Steindorf K (2018) Quality of life, problems, and needs of disease-free breast cancer survivors 5 years after diagnosis. Qual Life Res 27:2077\u20132086. https:\/\/doi.org\/10.1007\/s11136-018-1866-8","journal-title":"Qual Life Res"},{"key":"6670_CR3","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.breast.2021.06.012","volume":"59","author":"E Roine","year":"2021","unstructured":"Roine E, Sintonen H, Kellokumpu-Lehtinen PL, Penttinen H, Utriainen M, Vehmanen L, Huovinen R, Kautiainen H, Nikander R, Blomqvist C, Hakamies-Blomqvist L, Saarto T (2021) Long-term health-related quality of life of breast cancer survivors remains impaired compared to the age-matched general population especially in young women. Results from the prospective controlled BREX exercise study. Breast 59:110\u2013116. https:\/\/doi.org\/10.1016\/j.breast.2021.06.012","journal-title":"Breast"},{"key":"6670_CR4","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1093\/annonc\/mdp322","volume":"20","author":"A Goldhirsch","year":"2009","unstructured":"Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Th\u00fcrlimann B, Senn HJ (2009) Thresholds for therapies: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2009. Ann Oncol 20:1319\u20131329. https:\/\/doi.org\/10.1093\/annonc\/mdp322","journal-title":"Ann Oncol"},{"key":"6670_CR5","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx140","author":"DR Rivera","year":"2018","unstructured":"Rivera DR, Ganz PA, Weyrich MS, Bandos H, Melnikow J (2018) Chemotherapy-associated peripheral neuropathy in patients with early-stage breast cancer: a systematic review. J Natl Cancer Inst. https:\/\/doi.org\/10.1093\/jnci\/djx140","journal-title":"J Natl Cancer Inst"},{"key":"6670_CR6","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx162","author":"H Bandos","year":"2018","unstructured":"Bandos H, Melnikow J, Rivera DR, Swain SM, Sturtz K, Fehrenbacher L, Wade JL 3rd, Brufsky AM, Julian TB, Margolese RG, McCarron EC, Ganz PA (2018) Long-term peripheral neuropathy in breast cancer patients treated with adjuvant chemotherapy: NRG oncology\/NSABP B-30. J Natl Cancer Inst. https:\/\/doi.org\/10.1093\/jnci\/djx162","journal-title":"J Natl Cancer Inst"},{"key":"6670_CR7","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1200\/jco.1993.11.3.570","volume":"11","author":"DF Cella","year":"1993","unstructured":"Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J et al (1993) The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol 11:570\u2013579. https:\/\/doi.org\/10.1200\/jco.1993.11.3.570","journal-title":"J Clin Oncol"},{"key":"6670_CR8","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365\u2013376. https:\/\/doi.org\/10.1093\/jnci\/85.5.365","journal-title":"J Natl Cancer Inst"},{"key":"6670_CR9","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1200\/jco.1998.16.1.139","volume":"16","author":"D Osoba","year":"1998","unstructured":"Osoba D, Rodrigues G, Myles J, Zee B, Pater J (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16:139\u2013144. https:\/\/doi.org\/10.1200\/jco.1998.16.1.139","journal-title":"J Clin Oncol"},{"key":"6670_CR10","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1097\/01.Mlr.0000062554.74615.4c","volume":"41","author":"GR Norman","year":"2003","unstructured":"Norman GR, Sloan JA, Wyrwich KW (2003) Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 41:582\u2013592. https:\/\/doi.org\/10.1097\/01.Mlr.0000062554.74615.4c","journal-title":"Med Care"},{"issue":"89","key":"6670_CR11","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1200\/jco.2010.28.0107","volume":"29","author":"K Cocks","year":"2011","unstructured":"Cocks K, King MT, Velikova G, Martyn St-James M, Fayers PM, Brown JM (2011) Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the research and treatment of cancer Quality of Life Questionnaire Core 30. J Clin Oncol 29(89):96. https:\/\/doi.org\/10.1200\/jco.2010.28.0107","journal-title":"J Clin Oncol"},{"key":"6670_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jclinepi.2019.10.003","volume":"118","author":"JM Giesinger","year":"2020","unstructured":"Giesinger JM, Loth FLC, Aaronson NK, Arraras JI, Caocci G, Efficace F, Groenvold M, van Leeuwen M, Petersen MA, Ramage J, Tomaszewski KA, Young T, Holzner B (2020) Thresholds for clinical importance were established to improve interpretation of the EORTC QLQ-C30 in clinical practice and research. J Clin Epidemiol 118:1\u20138. https:\/\/doi.org\/10.1016\/j.jclinepi.2019.10.003","journal-title":"J Clin Epidemiol"},{"key":"6670_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01429-3","author":"K Engvall","year":"2021","unstructured":"Engvall K, Gr\u00e9en H, Fredriksson M, \u00c5vall-Lundqvist E (2021) Persistent neuropathy among early-stage breast cancer survivors in a population-based cohort. Br J Cancer. https:\/\/doi.org\/10.1038\/s41416-021-01429-3","journal-title":"Br J Cancer"},{"key":"6670_CR14","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1177\/1403494815602830","volume":"44","author":"SJ Olsson","year":"2016","unstructured":"Olsson SJ, Ekblom \u00d6, Andersson E, B\u00f6rjesson M, Kallings LV (2016) Categorical answer modes provide superior validity to open answers when asking for level of physical activity: a cross-sectional study. Scand J Public Health 44:70\u201376. https:\/\/doi.org\/10.1177\/1403494815602830","journal-title":"Scand J Public Health"},{"key":"6670_CR15","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1001\/archinte.158.16.1789","volume":"158","author":"K Bush","year":"1998","unstructured":"Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA (1998) The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol use disorders identification test. Arch Intern Med 158:1789\u20131795. https:\/\/doi.org\/10.1001\/archinte.158.16.1789","journal-title":"Arch Intern Med"},{"key":"6670_CR16","volume-title":"The EORTC QLQ-C30 scoring manual","author":"PMAN Fayers","year":"2001","unstructured":"Fayers PMAN, Bjordal K, Gorenvold M, Curran D, Bottomley A (2001) The EORTC QLQ-C30 scoring manual. European Organisation for Research and Treatment of Cancer, Brussels"},{"key":"6670_CR17","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.ejca.2014.11.024","volume":"51","author":"L Eckhoff","year":"2015","unstructured":"Eckhoff L, Knoop A, Jensen MB, Ewertz M (2015) Persistence of docetaxel-induced neuropathy and impact on quality of life among breast cancer survivors. Eur J Cancer 51:292\u2013300. https:\/\/doi.org\/10.1016\/j.ejca.2014.11.024","journal-title":"Eur J Cancer"},{"key":"6670_CR18","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/s0140-6736(11)61625-5","volume":"379","author":"R Peto","year":"2012","unstructured":"Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, Cutter D, Darby S, McGale P, Taylor C, Wang YC, Bergh J, Di Leo A, Albain K, Swain S, Piccart M, Pritchard K (2012) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379:432\u2013444. https:\/\/doi.org\/10.1016\/s0140-6736(11)61625-5","journal-title":"Lancet"},{"key":"6670_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004421.pub3","volume":"9","author":"ML Willson","year":"2019","unstructured":"Willson ML, Burke L, Ferguson T, Ghersi D, Nowak AK, Wilcken N (2019) Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev 9:Cd004421. https:\/\/doi.org\/10.1002\/14651858.CD004421.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"6670_CR20","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1200\/jco.2013.54.0914","volume":"32","author":"DL Hershman","year":"2014","unstructured":"Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, Chauhan C, Gavin P, Lavino A, Lustberg MB, Paice J, Schneider B, Smith ML, Smith T, Terstriep S, Wagner-Johnston N, Bak K, Loprinzi CL (2014) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 32:1941\u20131967. https:\/\/doi.org\/10.1200\/jco.2013.54.0914","journal-title":"J Clin Oncol"},{"key":"6670_CR21","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1200\/jco.20.01399","volume":"38","author":"CL Loprinzi","year":"2020","unstructured":"Loprinzi CL, Lacchetti C, Bleeker J, Cavaletti G, Chauhan C, Hertz DL, Kelley MR, Lavino A, Lustberg MB, Paice JA, Schneider BP, Lavoie Smith EM, Smith ML, Smith TJ, Wagner-Johnston N, Hershman DL (2020) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. J Clin Oncol 38:3325\u20133348. https:\/\/doi.org\/10.1200\/jco.20.01399","journal-title":"J Clin Oncol"},{"key":"6670_CR22","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.annonc.2020.07.003","volume":"31","author":"B Jordan","year":"2020","unstructured":"Jordan B, Margulies A, Cardoso F, Cavaletti G, Haugnes HS, Jahn P, Le Rhun E, Preusser M, Scott\u00e9 F, Taphoorn MJB, Jordan K (2020) Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up. Ann Oncol 31:1306\u20131319. https:\/\/doi.org\/10.1016\/j.annonc.2020.07.003","journal-title":"Ann Oncol"},{"key":"6670_CR23","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s10549-021-06477-0","volume":"192","author":"A Coolbrandt","year":"2022","unstructured":"Coolbrandt A, Vancoille K, Dejaeger E, Peeters H, Laenen A, Neven P, Punie K, Wildiers H (2022) Preventing taxane-related peripheral neuropathy, pain and nail toxicity: a prospective self-controlled trial comparing hilotherapy with frozen gloves in early breast cancer. Breast Cancer Res Treat 192:293\u2013301. https:\/\/doi.org\/10.1007\/s10549-021-06477-0","journal-title":"Breast Cancer Res Treat"},{"key":"6670_CR24","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1001\/jama.2013.2813","volume":"309","author":"EM Smith","year":"2013","unstructured":"Smith EM, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, Bressler LR, Fadul CE, Knox C, Le-Lindqwister N, Gilman PB, Shapiro CL (2013) Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 309:1359\u20131367. https:\/\/doi.org\/10.1001\/jama.2013.2813","journal-title":"JAMA"},{"key":"6670_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s11764-021-00997-w","author":"MAL Tanay","year":"2021","unstructured":"Tanay MAL, Armes J, Moss-Morris R, Rafferty AM, Robert G (2021) A systematic review of behavioural and exercise interventions for the prevention and management of chemotherapy-induced peripheral neuropathy symptoms. J Cancer Surviv. https:\/\/doi.org\/10.1007\/s11764-021-00997-w","journal-title":"J Cancer Surviv"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-022-06670-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-022-06670-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-022-06670-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,11]],"date-time":"2022-09-11T16:05:04Z","timestamp":1662912304000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-022-06670-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,9]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["6670"],"URL":"https:\/\/doi.org\/10.1007\/s10549-022-06670-9","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,9]]},"assertion":[{"value":"28 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The Regional Ethics Committee in Link\u00f6ping approved the study (Ref. No. 2016\/548-31). All women who participated in the study gave informed consent by returning the questionnaire. The study was performed in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study by the return of the postal questionnaire.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"This study contained no individual person\u2019s data.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}